Related Experiment Video
Updated: Jul 13, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
Glycemic variability and mortality in oncologic intensive care units
Aretha Pereira de Oliveira1, Mariana da Silva Castro2, Dalmo Valério Machado de Lima1
1Universidade Federal Fluminense. Niterói, Rio de Janeiro, Brazil.
Revista Brasileira De Enfermagem
|October 11, 2023
Summary
Glycemic variability, measured by general amplitude, is linked to mortality in cancer patients in intensive care. Monitoring this variability may improve patient management in oncologic intensive care units.
Area of Science:
- Oncology
- Critical Care Medicine
- Endocrinology
Background:
- Glycemic variability is a critical factor in patient outcomes.
- Its role in oncologic intensive care units (ICUs) requires further investigation.
Purpose of the Study:
- To examine the association between glycemic variability and mortality.
- To assess if glycemic variability predicts mortality in oncologic ICU patients.
Main Methods:
- Retrospective cohort study of 30 adult patients in oncologic ICUs.
- Glycemic variability assessed using standard deviation and general amplitude.
- Statistical analysis included ROC curve and AUC with 95% CI.
Main Results:
- General amplitude showed a significant association with mortality (p=.049).
- Standard deviation did not show a statistically significant association (p=.966).
- The study included 14 males (46.67%) with a mean age of 60±15 years.
Conclusions:
- General amplitude of glycemic variability is a significant predictor of mortality in oncologic ICUs.
- Monitoring glycemic variability may enhance critical care management for cancer patients.
- Further research is warranted to validate these findings.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
01:16Insulin: Dosing Regimen and Adverse Effects
185
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
185
01:22Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
01:06Oral Hypoglycemic Agents: Glinides
162
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
162
01:15Hypoglycemia and Glucagon
274
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
274
01:15Diabetes: Management and Pharmacotherapy
290
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
290